Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04504240
Status:
COMPLETED
Last Update Posted:
2021-10-26
First Post:
2020-08-06
Brief Title:
Role of Famotidine in the Clinical Improvement of COVID-19 Patients
Sponsor:
Chattogram General Hospital
Organization:
Chattogram General Hospital
Study Overview
Official Title:
Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is aimed to investigate the effect of Famotidine in the clinical recovery of COVID-19 patients COVID19 is a worldwide pandemic Hence SARS-CoV-2 is a novel virus there is no specific medication against it Like other countries of the world Besides antiviral drugs immunosuppressive agents and symptomatic therapy like H2 receptor blocker FAMOTIDINE came to the limelight due to its role in reducing the symptoms of COVID-19 patients The study will include COVID-19 participants to confirm by RT PCR or an HRCT chest Detail history of each participant with comorbidity will be taken and will be examined carefully The hospitalized patients admitted to the HDUICU units will be enrolled in this study Critically ill patients who require ventilator support will not be included in this study The outcome of the Famotidine treatment will be evaluated and compared with a control group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None